Literature DB >> 2069221

Maintenance of the patency of indwelling central venous catheters: is heparin necessary?

S Smith1, S Dawson, R Hennessey, M Andrew.   

Abstract

The use of indwelling central venous catheters for the ambulatory management of children with cancer has been well described. There remains uncertainty as to the best method for maintaining the patency of these catheters. The standard approach at our institution is to flush the catheter twice daily with a solution containing heparin. This is both costly and inconvenient for most families. We describe a randomized cross-over study designed to compare the standard approach to a less intense program using an isotonic saline flush once a week. Evaluation continued for approximately 1,515 days in each study arm. The catheters were monitored for blockage, clot formation, and infection. One catheter blocked in a patient receiving the experimental method of care. Two episodes of thrombus formation were demonstrated at the end of the study (one in each of the study arms). The incidence of infection, while in keeping with our overall experience, was higher in the experimental arm. This led to a subsequent study, reported separately in this symposium. The results indicate that there is no significant difference, in the incidence of blocked catheters or other complications, between the two forms of care.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2069221     DOI: 10.1097/00043426-199122000-00005

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  14 in total

1.  Anticoagulation and thrombolysis in children.

Authors:  M Andrew
Journal:  Tex Heart Inst J       Date:  1992

2.  Retention of lepirudin at the tip of a silicone catheter: a better catheter flush solution?

Authors:  McDonald K Horne; Elizabeth Inkellis
Journal:  Support Care Cancer       Date:  2004-02-13       Impact factor: 3.603

3.  Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long-term central venous catheters in infants and children.

Authors:  Natalie K Bradford; Rachel M Edwards; Raymond J Chan
Journal:  Cochrane Database Syst Rev       Date:  2020-04-30

4.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Central venous catheter use in UKCCSG oncology centres. United Kingdom Children's Cancer Study Group and the Paediatric Oncology Nursing Forum.

Authors:  D A Tweddle; K P Windebank; A M Barrett; D C Leese; R Gowing
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

Review 6.  Thrombolytic therapy for central venous catheter occlusion.

Authors:  Jacquelyn L Baskin; Ulrike Reiss; Judith A Wilimas; Monika L Metzger; Raul C Ribeiro; Ching-Hon Pui; Scott C Howard
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

7.  Survey of pharmacologic thromboprophylaxis in critically ill children.

Authors:  Edward Vincent S Faustino; Sonya Patel; Ravi R Thiagarajan; Deborah J Cook; Veronika Northrup; Adrienne G Randolph
Journal:  Crit Care Med       Date:  2011-07       Impact factor: 7.598

8.  Critical appraisal of surgical venous access in children.

Authors:  M A Hollyoak; T H Ong; J F Leditschke
Journal:  Pediatr Surg Int       Date:  1997-02       Impact factor: 1.827

Review 9.  Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis.

Authors:  E Vidal; A Sharathkumar; J Glover; E V S Faustino
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

Review 10.  Management of thrombotic complications in acute lymphoblastic leukemia.

Authors:  Ayesha N Zia; Meera Chitlur
Journal:  Indian J Pediatr       Date:  2013-08-04       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.